OPKO Health, Inc. (NASDAQ: OPK – Get Rating) CEO Phillip Md Et Al Frost bought 100,000 shares of the firm’s stock in a transaction on Thursday, June 16th. The stock was purchased at an average cost of $ 2.31 per share, for a total transaction of $ 231,000.00. Following the completion of the acquisition, the chief executive officer now owns 196,406,694 shares in the company, valued at $ 453,699,463.14. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Phillip Md Et Al Frost also recently made the following trade (s):
- On Monday, June 13th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $ 2.36 per share, for a total transaction of $ 236,000.00.
- On Monday, June 6th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $ 2.79 per share, for a total transaction of $ 279,000.00.
- On Tuesday, May 31st, Phillip Md Et Al Frost bought 50,000 shares of OPKO Health stock. The stock was purchased at an average cost of $ 3.02 per share, for a total transaction of $ 151,000.00.
- On Wednesday, May 25th, Phillip Md Et Al Frost bought 50,000 shares of OPKO Health stock. The stock was purchased at an average cost of $ 2.98 per share, for a total transaction of $ 149,000.00.
- On Wednesday, May 18th, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were bought at an average cost of $ 2.88 per share, for a total transaction of $ 144,000.00.
- On Monday, May 16th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were bought at an average cost of $ 2.98 per share, for a total transaction of $ 447,000.00.
- On Friday, May 13th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were bought at an average cost of $ 3.00 per share, for a total transaction of $ 600,000.00.
- On Tuesday, May 10th, Phillip Md Et Al Frost bought 400,000 shares of OPKO Health stock. The shares were acquired at an average cost of $ 2.78 per share, for a total transaction of $ 1,112,000.00.
Shares of NASDAQ OPK opened at $ 2.42 on Monday. The company has a market capitalization of $ 1.65 billion, a P / E ratio of -13.44 and a beta of 1.88. OPKO Health, Inc. has a 52-week low of $ 2.27 and a 52-week high of $ 5.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.12 and a current ratio of 2.44. The company 50 day moving average price is $ 2.92 and its 200-day moving average price is $ 3.44.
OPKO Health (NASDAQ: OPK – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($ 0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($ 0.06) by ($ 0.02). OPKO Health had a negative return on equity of 6.86% and a negative net margin of 7.49%. The firm had revenue of $ 329.20 million during the quarter, compared to analyst estimates of $ 331.45 million. During the same quarter last year, the firm posted $ 0.05 EPS. The firm’s revenue for the quarter was down 39.6% on a year-over-year basis. Analysts forecast that OPKO Health, Inc. will post -0.21 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of OPKO Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 36,072,131 shares of the biotechnology company stock valued at $ 124,088,000 after acquiring an additional 346,707 shares during the period. State Street Corp lifted its position in shares of OPKO Health by 56.7% during the 1st quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company stock valued at $ 95,250,000 after acquiring an additional 10,014,088 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of OPKO Health by 73.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company stock valued at $ 24,717,000 after acquiring an additional 3,037,320 shares during the period. Point72 Asset Management LP acquired a new position in OPKO Health during the fourth quarter worth $ 32,006,000. Finally, Norges Bank acquired a new position in OPKO Health during the fourth quarter worth $ 20,569,000. Institutional investors own 27.83% of the company stock.
A number of research firms have weighed in on OPK. Piper Sandler reduced their target price on shares of OPKO Health from $ 6.00 to $ 5.00 in a report on Tuesday, May 10th. TheStreet lowered shares of OPKO Health from a “c” rating to a “d +” rating in a report on Friday, February 25th. Finally, StockNews.com started coverage on shares of OPKO Health in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company stock. According to MarketBeat.com, OPKO Health currently has an average rating of “Hold” and a consensus price target of $ 6.00.
OPKO Health Company Profile: (Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics , hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Featured Stories:
Receive News & Ratings for OPKO Health Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com’s FREE daily email newsletter.
.